Butcher D - Search Results

1

Clinical significance of hyperbilirubinemia among HIV-1-infected patients treated with atazanavir/ritonavir through 96 weeks in the CASTLE study.

McDonald C, Uy J, Hu W, Wirtz V, Juethner S, Butcher D, McGrath D, Farajallah A, Moyle G. McDonald C, et al. Among authors: butcher d. AIDS Patient Care STDS. 2012 May;26(5):259-64. doi: 10.1089/apc.2011.0092. Epub 2012 Mar 9. AIDS Patient Care STDS. 2012. PMID: 22404426 Free PMC article. Clinical Trial.

2

Virologic suppression, treatment adherence, and improved quality of life on a once-daily efavirenz-based regimen in treatment-Naïve HIV-1-infected patients over 96 weeks.

Jayaweera D, Dejesus E, Nguyen KL, Grimm K, Butcher D, Seekins DW. Jayaweera D, et al. Among authors: butcher d. HIV Clin Trials. 2009 Nov-Dec;10(6):375-84. doi: 10.1310/hct1006-375. HIV Clin Trials. 2009. PMID: 20133268 Clinical Trial.

3

Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment.

Haubrich RH, Riddler SA, DiRienzo AG, Komarow L, Powderly WG, Klingman K, Garren KW, Butcher DL, Rooney JF, Haas DW, Mellors JW, Havlir DV; AIDS Clinical Trials Group (ACTG) A5142 Study Team. Haubrich RH, et al. AIDS. 2009 Jun 1;23(9):1109-18. doi: 10.1097/QAD.0b013e32832b4377. AIDS. 2009. PMID: 19417580 Free PMC article. Clinical Trial.

4

Initial viral decay to assess the relative antiretroviral potency of protease inhibitor-sparing, nonnucleoside reverse transcriptase inhibitor-sparing, and nucleoside reverse transcriptase inhibitor-sparing regimens for first-line therapy of HIV infection.

Haubrich RH, Riddler SA, Ribaudo H, Direnzo G, Klingman KL, Garren KW, Butcher DL, Rooney JF, Havlir DV, Mellors JW; AIDS Clinical Trials Group (ACTG) A5160 and A5142 Study Teams. Haubrich RH, et al. AIDS. 2011 Nov 28;25(18):2269-78. doi: 10.1097/QAD.0b013e32834d0c20. AIDS. 2011. PMID: 21941167 Free PMC article. Clinical Trial.

5

Predicting the short-term risk of diabetes in HIV-positive patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study.

Petoumenos K, Worm SW, Fontas E, Weber R, De Wit S, Bruyand M, Reiss P, El-Sadr W, Monforte AD, Friis-Møller N, Lundgren JD, Law MG; D:A:D Study Group. Petoumenos K, et al. J Int AIDS Soc. 2012 Oct 10;15(2):17426. doi: 10.7448/IAS.15.2.17426. J Int AIDS Soc. 2012. PMID: 23078769 Free PMC article.

6

Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: the D:A:D study.

Ryom L, Mocroft A, Kirk O, Worm SW, Kamara DA, Reiss P, Ross M, Fux CA, Morlat P, Moranne O, Smith C, Lundgren JD; D:A:D Study Group. Ryom L, et al. J Infect Dis. 2013 May 1;207(9):1359-69. doi: 10.1093/infdis/jit043. Epub 2013 Feb 4. J Infect Dis. 2013. PMID: 23382571 Free PMC article.

7

Non-AIDS defining cancers in the D:A:D Study--time trends and predictors of survival: a cohort study.

Worm SW, Bower M, Reiss P, Bonnet F, Law M, Fätkenheuer G, d'Arminio Monforte A, Abrams DI, Grulich A, Fontas E, Kirk O, Furrer H, De Wit S, Phillips A, Lundgren JD, Sabin CA; D:A:D Study Group. Worm SW, et al. BMC Infect Dis. 2013 Oct 9;13:471. doi: 10.1186/1471-2334-13-471. BMC Infect Dis. 2013. PMID: 24106926 Free PMC article.

8

Virologic response associated with a change in protease inhibitor therapy.

Butcher D, Greene J, Duong P, Markson L. Butcher D, et al. Arch Intern Med. 2000 Feb 14;160(3):394-5. doi: 10.1001/archinte.160.3.394-a. Arch Intern Med. 2000. PMID: 10668845 No abstract available.

9

Negative Pressure Dressings to Prevent Surgical Site Infection After Emergency Laparotomy: The SUNRRISE Randomized Clinical Trial.

SUNRRISE Trial Study Group; Atherton K, Brown J, Clouston H, Coe P, Duarte R, Dudi-Venkata NN, Duff S, Egoroff N, Fish R, Glasbey J, Ives N, Kaur M, Magill L, Mehta S, Pinkney T, Pockney P, Richards T, Sammour T, Sekhar H, Sinha Y, Stott M, Wilkin R. SUNRRISE Trial Study Group, et al. JAMA. 2025 Jan 27. doi: 10.1001/jama.2024.24764. Online ahead of print. JAMA. 2025. PMID: 39869330

10

Correction: Abcg2a is the functional homolog of human ABCG2 expressed at the zebrafish blood-brain barrier.

Thomas JR, Frye WJE, Robey RW, Warner AC, Butcher D, Matta JL, Morgan TC, Edmondson EF, Salazar PB, Ambudkar SV, Gottesman MM. Thomas JR, et al. Among authors: butcher d. Fluids Barriers CNS. 2025 Jan 3;22(1):2. doi: 10.1186/s12987-024-00606-9. Fluids Barriers CNS. 2025. PMID: 39754251 Free PMC article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

244 results

Search Page

Filters